INTRODUCTION

The SARS-CoV-2 virus continues to be a public health emergency due to the ongoing pandemic, which is now entering its third year. As per the latest World Health Organization (WHO) situation report, by January 11, 2022, above 300 million people have been infected by the SARS-CoV-2 virus since the start of the pandemic, with more than 5.4 million fatalities. COVID-19 is primarily a respiratory disease. The pulmonary complications are a sequela of parenchymal, vascular, or pleural involvement and range from pneumonia to acute respiratory distress syndrome (ARDS) and pulmonary embolism to pneumothorax. Pneumothorax, defined as air within the pleural space, is one of the emerging complications of COVID-19 infection. It can be primary (without any underlying lung disease) or secondary to chronic lung disease. If the air enters the pleural cavity but cannot leave, hence creating...
a one-way valve, and leads to mediastinal shift and associated decrease in venous return, cardiac output, and ultimately hypotension; then, it is referred to as tension pneumothorax, which is fatal, if left untreated. Multiple cases of COVID-19 infection complicated with the development of STP have been reported till date. This emerging complication of COVID-19 infection seems to have significant mortality. In addition, the diagnosis can be challenging given that COVID-19 infection may mask the symptoms of STP, as both may have similar symptomatology. This case report and detailed literature review highlight this severe complication of COVID-19, providing relevant insights to the physicians managing COVID-19 cases amid an ongoing pandemic.

2 | CASE PRESENTATION

A 40-year-old Filipino gentleman presented with a two-day history of sore throat and non-exertional shortness of breath. There was no history of fever or chest pain. The patient did not have any history of sick contacts, recent travel, immobilization, or recent surgery. He did not have any chronic medical illnesses, was not taking any medication, and was a non-smoker. On physical examination, he had a temperature of 36.5°C, blood pressure of 130/82 mmHg, and respiratory rate (RR) of 36 breaths/min. He was desaturating on room air to 82% and required 15 liters of oxygen via a non-rebreather mask to maintain oxygen saturation above 95%. The patient had pharyngeal erythema and bilateral coarse crackles on respiratory examination. Cardiac, gastrointestinal, and neurological examination were unremarkable. Complete blood count revealed lymphopenia but normal total white cell count, hemoglobin, and platelet counts. The metabolic profile showed hyponatremia, hypokalemia, elevated alanine aminotransferase (ALT), aspartate aminotransferase (AST), and lactate dehydrogenase. He also had an elevated C-reactive protein (CRP) and interleukin-6 (IL-6), but a normal d-dimer level (Table 1). A chest X-ray showed bilateral middle and lower zone infiltrates (Figure 1A). A reverse-transcriptase polymerase chain reaction (RT-PCR) nasopharyngeal swab was positive for SARS-CoV-2. The rest of the respiratory viral and blood cultures was negative for any other infective organism. Genomic testing was not performed to identify the strain of SARS-CoV-2. However, at the time of the patient’s presentation, the Delta variant (B.1.617.2) was prevalent in Qatar.

The patient was admitted to the intensive care unit as a case of severe COVID-19 pneumonia. As per the institutional protocol at the time, he was treated with intravenous (IV) ceftriaxone, azithromycin, methylprednisolone (40 mg every 12 hourly), and IV Remdesivir. Despite treatment, the patient’s condition did not improve, and on Day 5, intravenous immunoglobulin (IVIG) 0.4g/mlkg/day for three doses was initiated. On Days 6 and 7 of admission, he received two doses of IV tocilizumab 800mg. On Days 8 and 9, the patient received four units of convalescent plasma. The patient received multidisciplinary care throughout his admission, including physiotherapy, occupational therapy, respiratory therapy, dietetics, critical care, and infectious disease. On Day 14 of hospital stay, due to persistently high oxygen requirements and increasing D-dimers (peak 7.2 mg/L FEU), a CT pulmonary angiogram (CTPA) was performed to rule out pulmonary embolism. The scan showed no filling defect but showed predominantly peripheral and patchy basal areas of ground-glass attenuation with multifocal segmental dense consolidation with air bronchograms, consistent with severe bilateral pneumonia due to COVID-19.

After a period of stability, on Day 22 of hospitalization, the patient developed sudden tachypnea (41 breaths/min), and his oxygen requirements increased to 10 L and 40% FiO₂ to 15 L and 60% FiO₂ on venturi mask. Examination revealed a tracheal shift to the left side, a hyper-resonant percussion note with absent breath sounds on the right side of the chest. A bedside point-of-care ultrasound (POCUS) showed the “bar-code” sign and absence of sliding—a finding consistent with a right pneumothorax (Figure 2). A bedside CXR was performed, which confirmed a right-sided TP (Figure 1B).

---

**TABLE 1** Laboratory parameters of the patient at admission

| Parameter (normal range) | Results |
|--------------------------|---------|
| White cells (4–10 × 10³/mm³) | 5.9 |
| Neutrophil (2–7*10³/mm³) | 4.8 |
| Lymphocyte (1–3 × 10³/mm³) | 0.7 |
| Platelets (150–400 × 10³/mm³) | 166 |
| Hemoglobin (12.5–13.5 gm/dl) | 13.6 |
| Red Blood cells (4.5–5.5 10³/mm³) | 4.7 |
| ALT (0–55 Unit/L) | 269 |
| AST (5–34 Unit/L) | 87 |
| Creatinine (62–106 umol/L) | 81 |
| Sodium (mmol/L) | 128 |
| Potassium (mmol/L) | 3.3 |
| D-dimer (<mg/L FEU) | 0.36 |
| CRP (0–5 mg/L) | 83.1 |
| Procalcitonin (<0.5 ng/ml) | 0.36 |
| Ferritin (48–420 µg/L) | 1031 |
| Interleukin–6 (≤7 pg/ml) | 37 |

Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; CRP, C-reactive protein.
With a clinical and radiological diagnosis of tension pneumothorax, a 14 Fr Chest tube inserted using Seldinger technique was immediately placed and connected to under-water seal. Over the next five days, the patient’s pneumothorax improved with decreased oxygen requirement. However, due to persistent shortness of breath, oxygen requirement, and persistent bubbling, the patient’s chest tube could not be removed till two months later when his pneumothorax resolved, and he started to maintain normal oxygen saturation in room air. He was discharged afterward in an asymptomatic condition, with no evidence of pneumothorax recurrence six months following the discharge.

3 | DISCUSSION

The SARS-CoV-2 virus, a member of the coronavirus family, has caused over 300 million cases and more than 5.4 million deaths globally since its emergence in 2019. The B.1.1.529 variant (Omicron) is marked as the current variant of concern by WHO since November 2021 and is the cause of the recent wave of cases globally. Other than its direct and primary insult to the body, Coronavirus 2019 (COVID-19) may result in multimodal detrimental sequela, including secondary health-related complications, psychological effects, and socioeconomic impact at individual and global levels. Although most cases of COVID-19 infection exhibit primarily constitutional and respiratory tract symptoms (such as fever, fatigue, myalgias, dry or productive cough, and dyspnea) similar to any other pulmonary viral infection, it can cause any other organ/system to malfunction. This includes but is not limited to ocular, neurological, gastrointestinal, olfactory, gustatory, cardiac, hepatic, renal, hematological, and cutaneous manifestations.

Concerning the pulmonary manifestations of COVID-19, other than pneumonia and acute respiratory distress syndrome, various complications have been reported, which are not routinely seen in other types of respiratory viral infections. These include a prolonged infectious state, lung fibrosis, bullous lung disease, pleural effusion, pulmonary cysts, spontaneous pneumothorax, and pneumomediastinum, amongst others. Most of the patients who die from COVID-19 infection have the respiratory system as the primary organ involved. It is still unclear whether a specific mutation in the SARS-CoV-2 is more detrimental to the respiratory system than
Spontaneous tension pneumothorax (STP) is one of the most severe, life-threatening complications reported multiple times with COVID-19. STP can be primary, which mainly occurs in patients between 60 and 80 years, or secondary, which occurs in patients with pre-existing lung disease or a significant smoking history. It is not unexpected for patients with chronic lung disease who develop COVID-19 infection to have secondary STP as a complication. However, there are multiple reports of patients with only an acute respiratory insult due to COVID-19 infection, who developed STP without any other risk factors. It is imperative to identify the signs and symptoms of STP, especially in the setting of an ongoing respiratory infection, as sometimes the clinical features can overlap and may cause diagnostic and management delays. Clinical features of STP range from common findings such as dyspnea, chest pain, tachycardia to rare features such as cyanosis, epigastric pain, and unconsciousness. STP is a clinical and radiological diagnosis. It can be diagnosed by a point-of-care ultrasound, chest X-ray (CXR), or computed tomography (CT) scan. Patients on medical floors diagnosed with STP require an urgent escalation of care to intensive units for appropriate management, which is usually invasive. The usual management is a high flow oxygen supply followed by removal of the air from the pleural cavity, which can be done via emergency needle decompression with or without a chest tube insertion, depending on the clinical situation. Urgent needle decompression is the usual effective immediate treatment for STP; however, it has associated morbidity and complications. The needle is usually inserted at the second intercostal space above the rib in the midclavicular line and kept in place until a chest tube is inserted. An immediate CXR should follow this to assess the PTX resolution. When an STP results in a cardiac arrest, needle decompression is considered part of resuscitation to restore cardiac output.

After encountering and managing our patient with COVID-19 infection complicated by STP, we reviewed the available literature (from PubMed, Scopus, Cochrane Library, and Google Scholar) to identify similar cases. After reviewing 160 articles from title/abstract/keywords, and an in-depth review of 29 articles, we finalized 12 articles (1 case series and 11 case reports, for a total of 14 patients) which fulfilled the inclusion criteria to add to this literature review (no primary lung disease, COVID-19 infection confirmed with polymerase chain reaction test, confirmed diagnosis of STP clinically as well as radiologically). The data from these articles are presented in Table 2.

None of the patients had a prior history of PTX, which is also considered a risk factor for developing a recurrent PTX (recurrence rate is reported as high as 32%). Only one patient underwent intubation which could be argued as a reason for barotrauma-induced STP; however, the treating physicians associated the STP to the infection itself. Two patients were found to have bullae which were not diagnosed prior to the admission with COVID-19. As the bullae were diagnosed after COVID-19 infection, the treating physicians labeled them a manifestation of SARS-CoV-2 induced lung damage. Other than this, no other risk factors were identified in any of the other patients reported in the literature with COVID-19 infection complicated by STP. The patients had a median age of 52.5 years (ranging from 23 to 83 years). The median age in patients with STP without COVID-19 is reported to be the same (52.1 years) in a study of 320 patients.

Interestingly, 13 out of the 14 patients (92.8%) were males. Previous studies also show a male preponderance (up to 87%), and this difference can be associated to sample size variations. Generally, any PTX is more prevalent in men (around thrice as much), without any apparent reason. However, this difference is more pronounced in STP, especially in patients reported to have COVID-19 infection. 78.5% (n=11) of the patients did not have any baseline comorbid condition, including prior lung disease. Manifestations of STP in this patient group were similar to the standard presentations, including fever, cough, chest pain, and shortness of breath in most of the cases. However, these symptoms are identical to those secondary to the COVID-19 infection itself in the absence of STP. This presents a diagnostic challenge. Worsening of the same symptoms present at presentation with COVID-19 was reported in many cases, which is a diagnostic clue and a signal toward possible STP.

Another interesting point is the onset of STP from the start of COVID-19 infection, which seems to vary broadly. Five patients (35%) presented initially with STP, whereas it was reported to develop as late as Day 63 of COVID-19 infection. The patient who developed STP at day 63 had two episodes. For the first one, he was managed with a chest drain. However, eventually, pleurodesis was done on the second episode. This was the only patient where STP was recurrent.

Out of 14 patients, three died (2 due to worsening STP and respiratory distress and one due to cardiac arrest as a complication of STP). No specific pattern was found in the three patients who died concerning age, presenting symptoms, duration of STP, and its management. Due to scarce data in the literature, analyzing the factors related
### TABLE 2
Clinical characteristics and details of patients infected with SARS-CoV-2 who developed STP

| Cases | Age (y), Sex, comorbid | Symptoms | Radiological findings | SPTX onset | RF for SPTX | Tx | SPTX Duration (days) | LOS (days) | Outcome |
|-------|------------------------|----------|-----------------------|------------|-------------|----|---------------------|------------|---------|
| Case 1 | 36, M, no PMH | Cough, fever, and dyspnea: 3 weeks PCP: 4 h | CXR: large left-sided PTX, mediastinal shift, right lung consolidation | Day 1 | No | ND + CD | 2 | 4 | Resolved |
| Case 2 | 23, M, no PMH | Sudden onset epigastric pain and dyspnea | CXR: bilateral tension pneumothorax | Day 30 | No | ND + CD | 1 | 30 | Death |
| Case 3 | 83, M, no PMH | Worsening SOB and hypotension: 60/40 mmHg | CT: large left pneumothorax and ground-glass opacities in the right lung | NA | No | CD | NA | NA | Death |
| Case 4 | 62, M, T2D, HTN, PAD, CA, Previous PE | Dry cough, low grade fever, worsening SOB for 4 days, and PCP | CXR: large right-sided pneumothorax causing mediastinal shift | Day 1 | No | CD | 1 | 1 | Death |
| Case 5 | 56, M, no PMH | Fever (40.2°C), nonproductive cough, SOB for 4 days | CT: Tension pneumothorax on the left side, which caused shifting the heart and trachea to the right mediastinum | Day 1 | No | CD | 4 | 4 | Resolved |
| Case 6 | 59, M, no PMH | Cough, fever, and SOB | CXR: Left-sided STP | Day 11 | No | ND + CD | NA | NA | Resolved |
| Case 7 | 41, M, no PMH | 7-day history of SOB and fever | CXR: Large left-sided tension pneumothorax | Day 1 | No | CD | 7 | 19 | Resolved |
| Case 8 | 37, M, no PMH | Right-sided PCP, SOB of approximately 24-h duration | CXR: Large right pneumothorax with a leftward shift of the mediastinal structures | Day 14 | Rt. mid-lung bulla | CD | 5 | 5 | Resolved |
| Case 9 pt. 1 | 55, M, DM | Dyspnea, fever, sore throat cough for 1 week, Worsening of SOB 3 days | CXR-right sided pneumothorax with subcutaneous emphysema | Day−10 | No | CD | 2 | 22 | Resolved |
| Case 9 pt. 2 | 33, M, no PMH | Fever dry cough 5 days, dyspnea 3 days | CXR showed large right-sided pneumothorax | Day−15 | Large bullae | CD | 10 | NA | NA |
| Case 9 pt. 3 | 50, M, no PMH | Fever, dry cough, headache, dyspnea, worsening of SOB after 7 days of admission | CXR-right sided pneumothorax with a mediastinal shift | Day−7 | No | CD | 3 | NA | Resolved |
| Case 10 | 64, M, DM, HTN, Dyslipidemia | Fever, dry cough, progressive SOB 2 weeks | a large right-sided tension pneumothorax with mediastinal shift and diffuse airspace shadowing throughout the left lung, which was more pronounced peripherally | Day−1 | No | CD | 3 | 4 | Resolved |

(Continues)
TABLE 2 (Continued)

| Age (y), Sex, | SPTX Duration (days) | Radiological Findings          | Clinical Findings                                      | Tx          |
|------------|----------------------|--------------------------------|--------------------------------------------------------|-------------|
| CASE 1     | 55, M, no PMH        | 14 days on 1st STP, then another for 2nd STP | CT chest: a multiloculated right-sided tension pneumothorax | CD pleurodesis in 2nd presentation |
| CASE 2     | 33, F, no PMH        | 7 days                         | Clinically diagnosed                                   | Intubation  |
|            |                      |                                | Cough, SOB, myalgia 1 week                             | ND + CD     |

Abbreviations: CA, cancer; CD, chest drain; CRP, C-reactive protein; Env, investigations; IC, lymphocyte count; NA, not available; ND, needle decompression; PAD, peripheral arterial disease; PCP, pleuritic chest pain; PE, pulmonary embolism; PMH, past medical history; SOB, shortness of breath; STP, spontaneous tension pneumothorax; T2D, type II diabetes mellitus; Tx: treatment; WC, white blood cell count.

4 | CONCLUSION

Spontaneous tension pneumothorax should be included in the differential diagnosis of COVID-19 infected patients who have worsening symptoms or develop new respiratory symptoms during their hospital course. The management should be the same as any STP; however, an early diagnosis and prompt treatment may help reduce the seemingly higher than expected mortality with this complication of SARS-CoV-2 infection. More extensive studies are required to identify true prevalence and mortality rates as well as the factors associated with occurrence, as well as mortality in this patient population.

AUTHOR CONTRIBUTIONS

Zohaib Yousaf and Talat Saeed Chughtai case identification and eligibility assessment. Fateen Ata, Maya Omran, Dore Chikkahanasoge Ananthegowda, and Abdullah
ACKNOWLEDGMENTS
None.

CONFLICT OF INTEREST
The authors declare that they have no competing interests.

DATA AVAILABILITY STATEMENT
Data sharing is not applicable.

ETHICAL APPROVAL
Ethics approval for the case was obtained from Medical Research Center (MRC) Qatar (MRC-04–21–268).

CONSENT FOR PARTICIPATION AND PUBLICATION
Written informed consent was obtained from the patient for data and accompanying images prior to submission of this manuscript.

CONSENT
Written informed consent was obtained from the patient for publication of this case report and accompanying images.

ORCID
Fateen Ata https://orcid.org/0000-0001-7121-8574
Zohaib Yousaf https://orcid.org/0000-0002-4631-9899

REFERENCES
1. Weekly operational update on COVID-19 - 11 January 2022 [https://www.who.int/publications/m/item/weekly-operational-updates-on-covid-19---11-january-2022]
2. Johnson KD, Harris C, Cain JK, Hummer C, Goyal H, Perisetti A. Pulmonary and extra-pulmonary clinical manifestations of COVID-19. Front Med (Lausanne). 2020;7:526.
3. Imran JB, Eastman AL. Pneumothorax. JAMA. 2017;318(10):974.
4. Leigh-Smith S, Harris T. Tension pneumothorax—time for a rethink? Emerg Med J. 2005;22(1):8-16.
5. Al-Shokri SD, Ahmed AOE, Saleh AO, AbouKamar M, Ahmed K, Mohamed MFH. Case Report: COVID-19–related pneumothorax—case series highlighting a significant complication. Am J Trop Med Hyg. 2020;103(3):1166-1169.
6. Chandra V, Singp P, Hulligeri HS, Pandey M. Bilateral tension pneumothorax: an unusual complication in a COVID-19 recovered patient. Indian J Anaesth. 2021;65(7):556-557.
7. Flower L, Carter JPL, Rosales Lopez J, Henry AM. Tension pneumothorax in a patient with COVID-19. BMJ Case Rep. 2020;13(5):e235861.
8. Khurram R, Johnson FTF, Naran R, Hare S. Spontaneous tension pneumothorax and acute pulmonary emboli in a patient with COVID-19 infection. BMJ Case Rep. 2020;13(8):237475.
9. Mohamed A. Tension pneumothorax complicating COVID-19 pneumonia. Clin Case Rep. 2021;9(6):e04342.
10. Muhammad AI, Boynton EJ, Naureen S. COVID-19 with bilateral pneumothoraces- case report. Respir Med Case Rep. 2020;31:101254.
11. Nh SK, Muthirevula A, Rohan NH, Nh C, Lingaraju VC. Delayed COVID-19 sequel-A challenging case of recurrent spontaneous pneumothorax.
12. Perice L, Koit Z, Llovera I, Flanagan-Kundle MG. Spontaneous pneumothorax as a complication of COVID-19 pneumonia: a case report. Clin Pract Cases Emerg Med. 2020;4(4):521-523.
13. Rehnberg L, Chambers R, Lam S, Chamberlain M, Dushianthanan M. Recurrent pneumothorax in a critically ill ventilated COVID-19 patient. Case Rep Crit Care. 2020;2020:1-6.
14. Umar Shahzad M, Han J, Ramtoola MI, Lamprou V, Gupta U. Spontaneous tension pneumothorax as a complication of COVID-19. Case Rep Med. 2021;2021:1-4.
15. Vahidirad A, Sangjo A, Ghelichli M, Arian Natia A, Zandbaf T. Tension pneumothorax in patient with COVID-19 infection. Radiol Case Rep. 2021;16(2):358-360.
16. Yasukawa K, Yamadevan A, Rollins R. Bulla formation and tension pneumothorax in a patient with COVID-19. Am J Trop Med Hyg. 2020;103(3):943-944.
17. World Health Organization. Classification of Omicron (B.1.1.529): SARS-CoV-2 Variant of Concern.
18. Saladino V, Algeri D, Auriemma V. The psychological and social impact of COVID-19: new perspectives of well-being. Front Psychol. 2020;11(2550):577684.
19. Ata F, Montoro-Lopez MN, Awouda S, Elsukkar AMA, Badr AMH, Patel A. COVID-19 and heart failure: the big challenge. Heart Views. 2020;21(3):187-192.
20. Gurumurthy B, Das SK, Hiremath R, Shetty S, Hiremath A, Gowda T. Spectrum of atypical pulmonary manifestations of COVID-19 on computed tomography. Egyptian J Radiol Nucl Med. 2021;52(1):72.
21. Ahmad Alhiyari M, Ata F, Islam Aghizzawi M, Bint IBA, Salih Abdullha A, Yousaf Z. Post COVID-19 fibrosis, an emerging complication of SARS-CoV-2 infection. Idcasses. 2021;23:e01041.
22. Elezkurtaj S, Greuel S, Ihlow J, et al. Causes of death and co-morbidities in hospitalized patients with COVID-19. Sci Rep. 2021;11(1):4263.
23. Martinelli AW, Ingle T, Newman J, et al. COVID-19 and pneumothorax: a multicentre retrospective case series. Eur Respir J. 2020;56(5):2002697.
24. Greenberg DJ, Nabor C, Chandy D, Dhand A. Pneumothorax and pneumomediastinum in patients hospitalized with coronavirus disease 2019 (COVID-19). Heart Lung. 2021;50(3):386-387.
25. Zarougoudis P, Kioumis I, Pitsiou G, et al. Pneumothorax: from definition to diagnosis and treatment. J Thorac Dis. 2014;6:S372-S376.
26. Walker SP, Bibby AC, Halford P, Stadon L, White P, Maskell NA. Recurrence rates in primary spontaneous pneumothorax: a systematic review and meta-analysis. Eur Respir J. 2018;52(3):1800864.
27. Yoon JS, Choi SY, Suh JH, et al. Tension pneumothorax, is it a really life-threatening condition? *J Cardiothorac Surg*. 2013;8:197.

28. Comelli I, Bologna A, Ticinesi A, et al. Incidence of primary spontaneous pneumothorax is not associated with microclimatic variations. Results of a seven-year survey in a temperate climate area. *Monaldi Arch Chest Dis*. 2017;87(1):793.

29. Hoechter DJ, Speck E, Siegl D, Laven H, Zwissler B, Kammerer T. Tension pneumothorax during one-lung ventilation – an underestimated complication? *J Cardiothorac Vasc Anesth*. 2018;32(3):1398-1402.

How to cite this article: Ata F, Yousaf Z, Farsakoury R, et al. Spontaneous tension pneumothorax as a complication of Coronavirus disease 2019: Case report and literature review. *Clin Case Rep*. 2022;10:e05852. doi:10.1002/ccr3.5852